The BC Psychosis Program Biobank and Database for Genetic Polymorphisms and Their Associations With Psychosis Disorder (BCPP BIODA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02322918|
Recruitment Status : Unknown
Verified May 2016 by University of British Columbia.
Recruitment status was: Recruiting
First Posted : December 23, 2014
Last Update Posted : June 1, 2016
|Condition or disease||Intervention/treatment|
|Psychosis Schizophrenia||Genetic: Blood samples for whole genomic/transcriptomic sequencing|
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||200 participants|
|Target Follow-Up Duration:||6 Months|
|Official Title:||BC Psychosis Program Biobank and Database for Investigating Genetic Polymorphisms of Brain-derived Neurotrophic Factor and Catechol-o-methyl Transferase and Their Associations With Psychosis Disorder|
|Study Start Date :||July 2014|
|Estimated Primary Completion Date :||July 2018|
|Estimated Study Completion Date :||July 2018|
Participants admitted to BCPP
Blood or saliva samples will be collected from participants for whole genomic/transcriptomic sequencing
Genetic: Blood samples for whole genomic/transcriptomic sequencing
Participant will receive one blood draw whereby two samples will be extracted. If the participant wishes to participate in the study but is fearful of needles, they may be given the option to provide a saliva sample. A retrospective medical chart review will be performed after participant is discharged from BCPP in order to obtain a full phenotype. Genotyping of BDNF and COMT will be performed. Protein levels of BDNF will be determined. The remaining blood or saliva samples will be stored over the long-term in a biorepository at the BC Mental Health and Addictions Research Institute. A retrospective medical chart review will be completed after the participant is discharged.
- Creation of biorepository of blood samples for future genetic, proteonomic and pharmacogenomic studies. [ Time Frame: One visit during participant's stay at BCPP, an expected average of 6 months ]A biobank of stored samples will be used to determine the genetic variability in psychosis disorder.
- Identification of single-nucleotide polymorphisms (SNPs) in the BDNF and COMT genes [ Time Frame: One visit during participant's stay at BCPP, an expected average of 6 months ]We will determine if specific genetic variants in BDNF and COMT genes are associated with psychosis disorder severity, symptomology and resolution.
- Medical Chart Review [ Time Frame: One visit during participant's stay at BCPP, an expected average of 6 months ]A medical chart review will be done on hard-copy medical charts at BCPP.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02322918
|Contact: Delrae Fawcett, M.Sc.||604-875-2000 ext email@example.com|
|Contact: Heidi Boyda, Ph.D.||604-875-2000 ext firstname.lastname@example.org|
|Canada, British Columbia|
|University of British Columbia Hospital - BC Psychosis Program||Recruiting|
|Vancouver, British Columbia, Canada, V6T 2A1|
|Contact: Delrae Fawcett, M.Sc. 604-875-2000 ext 6115 email@example.com|
|Contact: Heidi N Boyda, Ph.D. 604-875-2000 ext 6484 firstname.lastname@example.org|
|Principal Investigator: Alasdair M Barr, Ph.D.|
|Principal Investigator:||Alasdair M Barr, Ph.D.||University of British Columbia|